Association of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trial

Trojan, J.Abou-Alfa, G. K.Meyer, T.Cheng, A. -L.Cicin, I.Bolondi, L.Kluempen, H. J.2024-06-122024-06-1220192296-52702296-5262https://hdl.handle.net/20.500.14551/26791[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Association of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trialConference Object42243243Q4WOS:000568159600586